litlas
Log inCreate account

Oliver G. Ottmann

Active 1988–2025

100
Papers
19,893
Citations
81
h-index
100
i10-index

Citations

Citations per year for Oliver G. Ottmann1988: 2 citations1989: 15 citations1990: 22 citations1991: 23 citations1992: 25 citations1993: 21 citations1994: 7 citations1995: 22 citations1996: 11 citations1997: 10 citations1998: 14 citations1999: 4 citations2000: 22 citations2001: 19 citations2002: 54 citations2003: 81 citations2004: 76 citations2005: 106 citations2006: 116 citations2007: 220 citations2008: 154 citations2009: 154 citations2010: 160 citations2011: 149 citations2012: 189 citations2013: 167 citations2014: 184 citations2015: 171 citations2016: 171 citations2017: 162 citations2018: 139 citations2019: 578 citations2020: 592 citations2021: 548 citations2022: 426 citations2023: 280 citations2024: 517 citations2025: 216 citations2026: 3 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,187 citing papers, 28.7% of this breakdownGermany: 756 citing papers, 9.9% of this breakdownChina: 521 citing papers, 6.9% of this breakdownItaly: 460 citing papers, 6% of this breakdownUnited Kingdom: 441 citing papers, 5.8% of this breakdownFrance: 352 citing papers, 4.6% of this breakdownSpain: 241 citing papers, 3.2% of this breakdownAustralia: 239 citing papers, 3.1% of this breakdownCanada: 207 citing papers, 2.7% of this breakdownNetherlands: 206 citing papers, 2.7% of this breakdownJapan: 192 citing papers, 2.5% of this breakdownSwitzerland: 181 citing papers, 2.4% of this breakdown
0%28.7%Other 21.5%

Institutions

Fields

  • Medicine73%
  • Biochemistry, Genetics and Molecular Biology16.2%
  • Immunology and Microbiology8.8%
  • Pharmacology, Toxicology and Pharmaceutics0.5%
  • Computer Science0.4%
  • Neuroscience0.3%
  • Other0.8%

Topics

  • Acute Myeloid Leukemia Research9.5%
  • Chronic Myeloid Leukemia Treatments9.5%
  • CAR-T cell therapy research7%
  • Acute Lymphoblastic Leukemia research6.2%
  • Chronic Lymphocytic Leukemia Research4.6%
  • Immune Cell Function and Interaction4.4%
  • Other58.8%

Coauthors

All papers

Open in search
  1. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

    Authors: Timothy P. Hughes, Michael J. Mauro, Jörge E. Cortes, Hironobu Minami, Delphine Réa, Daniel J. DeAngelo, Massimo Breccia, Yeow-Tee Goh, Moshe Talpaz, Andreas Hochhaus, Philipp le Coutre, Oliver G. Ottmann, Michael C. Heinrich, Juan Luis Steegmann, Michael W. Deininger, Jeroen J. W. M. Janssen, François-Xavier Mahon, Yosuke Minami, David T Yeung, David M. Ross, Martin S. Tallman, Jae H. Park, Brian Druker, David Hynds, Yuyan Duan, Christophe Meille, Florence Hourcade‐Potelleret, K. Gary J. Vanasse, Fabian Lang, Dong‐Wook Kim - New England Journal of Medicine 2019 cited by 467

  2. Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy

    Authors: Garry Dolton, Cristina Rius, Aaron Wall, Barbara Szomolay, Valentina Bianchi, Sarah A. E. Galloway, Md Samiul Hasan, Théo Morin, Marine E. Caillaud, Hannah Thomas, Sarah M. Theaker, Li Rong Tan, Anna Fuller, Katie Topley, Mateusz Legut, Meriem Attaf, Jade R. Hopkins, Enas M. Behiry, Joanna Zabkiewicz, Caroline Alvares, Angharad Lloyd, Amber Rogers, Peter Henley, Chris Fegan, Oliver G. Ottmann, Stephen Man, Michael D. Crowther, Marco Donia, Inge Marie Svane, David K. Cole, Paul E. Brown, P.J. Rizkallah, Andrew K. Sewell - Cell 2023 cited by 140

  3. Treatment of patients with advanced cancer with the natural killer cell line NK-92

    Authors: Torsten Tonn, Dirk Schwabe, Hans Klingemann, Sven Becker, Ruth Esser, Ulrike Koehl, Meinolf Suttorp, Erhard Seifried, Oliver G. Ottmann, Gesine Bug - Cytotherapy 2013 cited by 471

  4. Unified classification and risk-stratification in Acute Myeloid Leukemia

    Authors: Yanis Tazi, Juan E. Arango‐Ossa, Yangyu Zhou, Elsa Bernard, Ian Thomas, Amanda Gilkes, Sylvie Freeman, Yoann Pradat, Sean Johnson, Robert K. Hills, Richard Dillon, Max F. Levine, Daniel Leongamornlert, Adam P. Butler, Arnold Ganser, Lars Bullinger, Konstanze Döhner, Oliver G. Ottmann, Richard Adams, Hartmut Döhner, Peter J. Campbell, Alan K. Burnett, Michael Dennis, Nigel H. Russell, Sean M. Devlin, Brian J.P. Huntly, Elli Papaemmanuil - Nature Communications 2022 cited by 175

  5. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

    Authors: Jörge E. Cortes, Florian H. Heidel, Andrzej Hellmann, Walter Fiedler, B. Douglas Smith, Tadeusz Robak, Pau Montesinos, Daniel A. Pollyea, Pierre DesJardins, Oliver G. Ottmann, Weidong Wendy, M. Naveed Shaik, Alexander Laird, Mirjana Zeremski, Ashleigh O’Connell, Geoffrey Chan, Michael Heuser - Leukemia 2018 cited by 489

  6. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL

    Authors: Philippe Rousselot, marie Magdelaine Coude, Nicola Gökbuget, Carlo Gambacorti‐Passerini, Sandrine Hayette, Jean‐Michel Cayuela, Françoise Huguet, Thibaut Leguay, Patrice Chevallier, Célia Salanoubat, Caroline Bonmati, Magda Alexis, Mathilde Hunault, Sylvie Glaisner, Philippe Agapé, Christian Berthou, Éric Jourdan, José Fernandes, Laurent Sutton, Anne Banos, Oumédaly Reman, Bruno Lioure, Xavier Thomas, Norbert Ifrah, Mårina Lafage‐Pochitaloff, Anne Bornand, Laure Morisset, Valérie Robin, Heike Pfeifer, André Delannoy, Josep‐María Ribera, Renato Bassan, Marc Delord, Dieter Hoelzer, Hervé Dombret, Oliver G. Ottmann - Blood 2016 cited by 326

  7. Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study

    Authors: Giovanni Martinelli, Nicolas Boissel, Patrice Chevallier, Oliver G. Ottmann, Nicola Gökbuget, Max S. Topp, Adele K. Fielding, Alessandro Rambaldi, Ellen K. Ritchie, Cristina Papayannidis, Lulu Ren Sterling, Jonathan Benjamin, Anthony S. Stein - Journal of Clinical Oncology 2017 cited by 446

  8. CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells

    Authors: Mateusz Legut, Garry Dolton, Afsar Mian, Oliver G. Ottmann, Andrew K. Sewell - Blood 2017 cited by 225

  9. Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

    Authors: Max S. Topp, Peter Kufer, Nicola Gökbuget, Mariele Goebeler, Matthias Klinger, Svenja Neumann, Heinz-A. Horst, Thorsten Raff, Andreas Viardot, Mathias Schmid, Matthias Stelljes, Markus Schaich, Evelyn Degenhard, R Köhne-Volland, Monika Brüggemann, Oliver G. Ottmann, Heike Pfeifer, Thomas Burmeister, Dirk Nagorsen, Margit Schmidt, Ralf Lutterbuese, Carsten Reinhardt, Patrick A. Baeuerle, Michael Kneba, Hermann Einsele, Gert Riethmüller, Dieter Hoelzer, Gerhard Zugmaier, Ralf C. Bargou - Journal of Clinical Oncology 2011 cited by 913

  10. Idasanutlin Plus Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia: Results of the MIRROS Trial

    Authors: Marina Konopleva, Christoph Röllig, Jamie Cavenagh, Dries Deeren, Larisa Girshova, Jürgen Krauter, Giovanni Martinelli, Pau Montesinos, Jonas Schäfer, Oliver G. Ottmann, Mario Petrini, Arnaud Pigneux, Alessandro Rambaldi, Christian Récher, Rebeca Rodríguez‐Veiga, David Taussig, Norbert Vey, Sung‐Soo Yoon, Marion Ott, Susanne Muehlbauer, Benjamin M. Beckermann, Olivier Catalani, Magali Genevray, Kirsten Mundt, Candice Jamois, Pierre Fenaux, Andrew H. Wei - Blood Advances 2022 cited by 70

  11. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results

    Authors: Michael J. Mauro, Timothy P. Hughes, Dong‐Wook Kim, Delphine Réa, Jörge E. Cortes, Andreas Hochhaus, Koji Sasaki, Massimo Breccia, Moshe Talpaz, Oliver G. Ottmann, Hironobu Minami, Yeow Tee Goh, Daniel J. DeAngelo, Michael C. Heinrich, Valle Gómez-Garcı́a de Soria, Philipp le Coutre, François‐Xavier Mahon, Jeroen J. W. M. Janssen, Michael W. Deininger, Naranie Shanmuganathan, Mark B. Geyer, Silvia Cacciatore, Fotis Polydoros, Nithya Agrawal, Matthias Hoch, Fabian Lang - Leukemia 2023 cited by 47

  12. Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study

    Authors: Andrew M. Brunner, Jordi Esteve, Kimmo Porkka, Steven Knapper, Elie Traer, Sebastian Scholl, Guillermo Garcia‐Manero, Norbert Vey, Martin Wermke, Jeroen Janssen, Rupa Narayan, Sun Loo, Mika Kontro, Oliver G. Ottmann, Purushotham Naidu, Marc R. Pelletier, May Han, Andrew Lewandowski, Na Zhang, Anisa Mohammed, Mikael L. Rinne, Uma Borate, Andrew H. Wei, Natalia Tovar - Blood 2021 cited by 101

  13. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes

    Authors: Andrew M. Brunner, Jordi Esteve, Kimmo Porkka, Steven Knapper, Elie Traer, Sebastian Scholl, Guillermo Garcia‐Manero, Norbert Vey, Martin Wermke, Jeroen J. W. M. Janssen, Rupa Narayan, Shaun Fleming, Sun Loo, Natalia Tovar, Mika Kontro, Oliver G. Ottmann, Purushotham Naidu, Haiying Sun, May Han, Roisin White, Na Zhang, Anisa Mohammed, Catherine Sabatos-Peyton, David P. Steensma, Mikael L. Rinne, Uma Borate, Andrew H. Wei - American Journal of Hematology 2023 cited by 46

  14. CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies

    Authors: A Romański, Christoph Uherek, Gesine Bug, Erhard Seifried, Hans Klingemann, Winfried S. Wels, Oliver G. Ottmann, Torsten Tonn - Journal of Cellular and Molecular Medicine 2016 cited by 224

  15. Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome–positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study

    Authors: Giovanni Martinelli, Nicolas Boissel, Patrice Chevallier, Oliver G. Ottmann, Nicola Gökbuget, Alessandro Rambaldi, Ellen K. Ritchie, Cristina Papayannidis, Catherine Tuglus, Joan Morris, Anthony S. Stein - European Journal of Cancer 2021 cited by 93

  16. Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel

    Authors: Nicola Gökbuget, Nicolas Boissel, Sabina Chiaretti, Hervé Dombret, Michael Doubek, Adele K. Fielding, Robin Foà, Sebastian Giebel, Dieter Hoelzer, Mathilde Hunault, David I. Marks, Giovanni Martinelli, Oliver G. Ottmann, Anita W. Rijneveld, Philippe Rousselot, Josep‐María Ribera, Renato Bassan - Blood 2024 cited by 76

  17. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma

    Authors: Sarah Oelsner, Miriam E. Friede, Congcong Zhang, Juliane Wagner, Susanne Badura, Peter Bader, Evelyn Ullrich, Oliver G. Ottmann, Hans Klingemann, Torsten Tonn, Winfried S. Wels - Cytotherapy 2016 cited by 187

  18. Management of ALL in adults: 2024 ELN recommendations from a European expert panel

    Authors: Nicola Gökbuget, Nicolas Boissel, Sabina Chiaretti, Hervé Dombret, Michael Doubek, Adele K. Fielding, Robin Foà, Sebastian Giebel, Dieter Hoelzer, Mathilde Hunault, David I. Marks, Giovanni Martinelli, Oliver G. Ottmann, Anita W. Rijneveld, Philippe Rousselot, Josep‐María Ribera, Renato Bassan - Blood 2024 cited by 109

  19. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome–positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

    Authors: Sebastian Giebel, Anna Czyż, Oliver G. Ottmann, Frédéric Baron, Éolia Brissot, Fabio Ciceri, Jan J. Cornelissen, Jordi Esteve, Norbert Claude Gorin, Bipin N. Savani, Christoph Schmid, Mohamad Mohty, Arnon Nagler - Cancer 2016 cited by 188

  20. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes

    Authors: Felicitas Thol, Sofia Kade, Carola Schlarmann, Patrick Löffeld, Michael Morgan, Jürgen Krauter, Marcin W. Włodarski, Britta Kölking, Martin Wichmann, Kerstin Görlich, Gudrun Göhring, Gesine Bug, Oliver G. Ottmann, Charlotte M. Niemeyer, Wolf‐Karsten Hofmann, Brigitte Schlegelberger, Arnold Ganser, Michael Heuser - Blood 2012 cited by 418

  21. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

    Authors: Hagop M. Kantarjian, Francis J. Giles, Kapil N. Bhalla, Javier Pinilla‐Ibarz, Richard A. Larson, Norbert Gattermann, Oliver G. Ottmann, Andreas Hochhaus, Jerald P. Radich, Giuseppe Saglio, Timothy P. Hughes, Giovanni Martinelli, Dong-Wook Kim, Yaping Shou, Neil J. Gallagher, Rick E. Blakesley, Michele Baccarani, Jörge E. Cortes, Philipp D. le Coutre - Blood 2010 cited by 379

  22. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia

    Authors: Éolia Brissot, Myriam Labopin, M. Beckers, Gèrard Socié, Alessandro Rambaldi, Liisa Volin, Jürgen Finke, Stig Lenhoff, Nicolaus Kröger, G.J. Ossenkoppele, Charles Craddock, Ibrahim Yakoub‐Agha, Günhan Gürman, NH Russell, Mahmoud Aljurf, Mike Potter, A. Nagler, Oliver G. Ottmann, Jan J. Cornelissen, Jacques Estève, Mohamad Mohty - Haematologica 2014 cited by 162

  23. Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML

    Authors: Faisal Basheer, George Giotopoulos, Eshwar Meduri, Haiyang Yun, Milena Mazan, Daniel Sasca, Paolo Gallipoli, Ludovica Marando, Malgorzata Gozdecka, Ryan Asby, Olivia Sheppard, Monika Dudek, Lars Bullinger, Hartmut Döhner, Richard Dillon, Sylvie Freeman, Oliver G. Ottmann, Alan K. Burnett, Nigel H. Russell, Elli Papaemmanuil, Robert K. Hills, Peter J. Campbell, George S. Vassiliou, Brian J.P. Huntly - The Journal of Experimental Medicine 2019 cited by 123

  24. Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL

    Authors: Hagop M. Kantarjian, Francis J. Giles, Lydia Wunderle, Kapil N. Bhalla, Susan O’Brien, Barbara Waßmann, Chiaki Tanaka, Paul W. Manley, P. Rae, William Mietlowski, Kathy Bochinski, Andreas Hochhaus, James D. Griffin, Dieter Hoelzer, Maher Albitar, Margaret Dugan, Jörge E. Cortes, Leila Alland, Oliver G. Ottmann - New England Journal of Medicine 2006 cited by 1,345